[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Eosinophilic Esophagitis - Pipeline Review, H1 2020

April 2020 | 131 pages | ID: E685D79D924EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Eosinophilic Esophagitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2020, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 3, 2 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Eosinophilic Esophagitis - Overview
Eosinophilic Esophagitis - Therapeutics Development
Eosinophilic Esophagitis - Therapeutics Assessment
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
Eosinophilic Esophagitis - Drug Profiles
Eosinophilic Esophagitis - Dormant Projects
Eosinophilic Esophagitis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Eosinophilic Esophagitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H1 2020
Eosinophilic Esophagitis - Pipeline by Allakos Inc, H1 2020
Eosinophilic Esophagitis - Pipeline by Arena Pharmaceuticals Inc, H1 2020
Eosinophilic Esophagitis - Pipeline by Banner Life Sciences LLC, H1 2020
Eosinophilic Esophagitis - Pipeline by Bristol-Myers Squibb Co, H1 2020
Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H1 2020
Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H1 2020
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2020
Eosinophilic Esophagitis - Pipeline by EsoCap AG, H1 2020
Eosinophilic Esophagitis - Pipeline by GlaxoSmithKline Plc, H1 2020
Eosinophilic Esophagitis - Pipeline by Humanigen Inc, H1 2020
Eosinophilic Esophagitis - Pipeline by Kyowa Kirin Co Ltd, H1 2020
Eosinophilic Esophagitis - Pipeline by Morphic Holding Inc, H1 2020
Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H1 2020
Eosinophilic Esophagitis - Pipeline by RAPT Therapeutics Inc, H1 2020
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Eosinophilic Esophagitis - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H1 2020
Eosinophilic Esophagitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Eosinophilic Esophagitis - Dormant Projects, H1 2020

LIST OF FIGURES

Number of Products under Development for Eosinophilic Esophagitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Adare Pharmaceuticals Inc
Allakos Inc
Arena Pharmaceuticals Inc
Banner Life Sciences LLC
Bristol-Myers Squibb Co
Calypso Biotech SA
DBV Technologies SA
Dr. Falk Pharma GmbH
EsoCap AG
GlaxoSmithKline Plc
Humanigen Inc
Kyowa Kirin Co Ltd
Morphic Holding Inc
Quorum Innovations LLC
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Suzhou Connect Biopharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd


More Publications